Core Insights - SCTbio and Fortrea have announced a strategic collaboration to enhance the development and delivery of advanced therapies, aiming to streamline processes and accelerate timelines for bringing therapies to patients [1][2][3] Company Overview - SCTbio is a leading Contract Development and Manufacturing Organization (CDMO) with over 15 years of experience in GMP manufacturing for Advanced Therapy Medicinal Products (ATMPs), providing end-to-end services including apheresis materials, vector production, and quality control [4] - Fortrea is a global provider of clinical development solutions, partnering with biopharmaceutical and biotechnology companies to drive healthcare innovation across various therapeutic areas, leveraging three decades of experience [6] Collaboration Details - The partnership aims to create synchronized solutions that de-risk programs, streamline planning, and optimize cost-efficiency throughout the development lifecycle, addressing over 4,400 gene, cell, and RNA therapies currently in development [2][3] - By combining Fortrea's clinical reach with SCTbio's manufacturing expertise, the collaboration seeks to enhance protocol design, supply chain resilience, and the delivery of therapies globally [3] - The collaboration will align clinical trial logistics with GMP manufacturing readiness, ensuring synchronized planning and execution for cell and gene therapy programs [3]
SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery